Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, October 1998, p. 2495-2502, Vol. 42, No. 10
Department of Medicine, Division of
Infectious Diseases and International Health, Duke University Medical
Center, Durham, North Carolina 277101;
Department of Pathobiology, Auburn University, Auburn, Alabama
368493;
Department of Pathology and
Laboratory Medicine, University of North Carolina at Chapel Hill,
Chapel Hill, North Carolina 275994;
Department of Chemistry, Georgia State University, Atlanta,
Georgia 303035; and
Institute of
Infectious Diseases and Public Health, University of Ancona,
Ospedale Umberto I°, 60121 Ancona, Italy2
Received 13 February 1998/Returned for modification 1 April
1998/Accepted 10 July 1998
Twenty analogues of pentamidine, 7 primary metabolites of
pentamidine, and 30 dicationic substituted bis-benzimidazoles
were screened for their inhibitory and fungicidal activities against Candida albicans and Cryptococcus
neoformans. A majority of the compounds had MICs at which 80% of
the strains were inhibited (MIC80s) comparable to those of
amphotericin B and fluconazole. Unlike fluconazole, many of these
compounds were found to have potent fungicidal activity. The most
potent compound against C. albicans had an
MIC80 of
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Structure-In Vitro Activity Relationships of Pentamidine
Analogues and Dication-Substituted Bis-Benzimidazoles as New
Antifungal Agents
0.09 µg/ml, and the most potent compound against C. neoformans had an MIC80 of 0.19 µg/ml. Selected compounds were also found to be active against
Aspergillus fumigatus, Fusarium solani,
Candida species other than C. albicans, and fluconazole-resistant strains of C. albicans and C. neoformans. It is clear from the data
presented here that further studies on the structure-activity relationships, mechanisms of action and toxicities, and in vivo efficacies of these compounds are warranted to determine their clinical
potential.
*
Corresponding author. Mailing address: Department of
Medicine, Division of Infectious Diseases and International Health,
Duke University Medical Center, P.O. Box 3353, Durham, NC 27710. Phone: (919) 684-2660. Fax: (919) 684-8902. E-mail: perfe001{at}mc.duke.edu.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |